Consistently, Sase et al. described that RUNX2 immuno-reactivity in colon cancer cells is associated with their aggressive clinical behavior and its higher expression level is mediated by the stimulation of PI3K/AKT pathway [149]. Here, AKT1 is linked to malignant colon neoplasm.